ArticleScientific reports2025
Improved vascular response to a novel polymeric blend PLLA/PLGA coronary scaffold material: preclinical study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TLR2 inhibition attenuates NET-driven inflammation and restenosis during poly-lactic acid bioresorbable scaffold degradation.Bioactive materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thick struts and polymeric crystalline material are the potential mechanism of failure of the first generation bioresorbable scaffolds (BRS). We evaluated a novel fully amorphous bioresorbable scaffold (BRS) made of poly-L-lactide/poly-L-glycolide (PLLA/PLGA, Apollo, Biostent Consortium, Poland) in a porcine coronary restenosis model. Uncoated BRS (PLLA 120 μm, n = 7; PLLA 150 μm, n = 8; PLLA/PLGA 200 μm, n = 10) were implanted in 12 swine using OCT guidance and 110% overstretch. Follow-up included angiography, OCT, and histopathology at 30 and 90 days. At 30 days, OCT showed no significant differences in stenosis or neointimal hyperplasia between groups as represented by percent area stenosis (PLLA 120: 41% ± 17, PLLA 150: 52 ± 20%, PLLA/PLGA: 55 ± 6%; p = 0.07 ) and neointimal area (PLLA 120: 2.01 ± 0.8 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.